Atara Biotherapeutics, Inc.
General ticker "ATRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $114.1M (TTM average)
Atara Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 50.4%.
Estimated limits based on current volatility of 6.7%: low 12.21$, high 13.95$
Factors to consider:
- Total employees count: 35 as of 2024
- Top business risk factors: Regulatory and compliance, Clinical trial disruptions, Market competition, Supply chain disruptions, Economic downturns and volatility
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.29$, 19.91$]
- 2025-12-31 to 2026-12-31 estimated range: [4.63$, 15.19$]
Financial Metrics affecting the ATRA estimates:
- Negative: with PPE of -0.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -76.20 <= 0.33
- Negative: Shareholder equity ratio, % of -89.17 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Inventory ratio change, % of 49.25 > 0.84
Short-term ATRA quotes
Long-term ATRA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $63.57MM | $8.57MM | $128.94MM |
| Operating Expenses | $344.09MM | $284.58MM | $212.38MM |
| Operating Income | $-280.51MM | $-276.01MM | $-83.44MM |
| Non-Operating Income | $52.22MM | $-0.10MM | $-1.98MM |
| Interest Expense | $0.37MM | $5.29MM | $4.62MM |
| R&D Expense | $272.53MM | $224.78MM | $151.48MM |
| Income(Loss) | $-228.29MM | $-276.11MM | $-85.42MM |
| Taxes | $0.01MM | $0.01MM | $-0.01MM |
| Profit(Loss)* | $-228.30MM | $-276.13MM | $-85.40MM |
| Stockholders Equity | $126.64MM | $-99.23MM | $-97.28MM |
| Inventory | $1.59MM | $9.71MM | $10.65MM |
| Assets | $376.42MM | $165.50MM | $109.10MM |
| Operating Cash Flow | $-270.43MM | $-192.98MM | $-68.72MM |
| Capital expenditure | $4.19MM | $1.22MM | $0.25MM |
| Investing Cash Flow | $202.96MM | $123.87MM | $8.62MM |
| Financing Cash Flow | $53.08MM | $2.01MM | $59.28MM |
| Earnings Per Share** | $-55.96 | $-65.18 | $-11.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.